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Metabolism and cancer: the future is now
In the last decade, the field of cancer metabolism transformed itself from being a description of the metabolic features of cancer cells
to become a key component of cellular transformation. Now, the potential role of this field in cancer biology is ready to be unravelled.
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BACKGROUND
If we look back 10 years ago, the main questions in the field of
cancer metabolism were whether and why cancer cells exhibited
the so-called “Warburg effect”, a metabolic switch from oxidative
to glycolytic metabolism. For years it was unclear why fast
proliferating cancer cells would undergo this metabolic switch
considered by many an inefficient use of nutrients (reviewed in 1).
This fervid discussion was epitomised by a landmark review from
Vander Heiden and colleagues,2 who proposed that the “Warburg
effect” should not be viewed solely from the point of view of
energy generation, but, instead, should be considered as a mean
to synthesise anabolic molecules. This change in perspective,
almost a new Weltanschauung for the field, fostered new lines of
enquiries to determine how cancer cells fulfil their biosynthetic
needs, and connected the “Warburg effect” to nucleotide, lipids,
and protein metabolism. Nowadays, we are facing another
revolution. After years spent charting the many metabolic
pathways explored by cancer cells to retrieve nutrients for growth
and proliferation, the community has realised that the metabolic
layer is at the interface between many other cellular processes in
the cells and that it is more heterogeneous and subject to external
cues than anticipated. In this second instalment of the special
issue on Cancer Metabolism in the British Journal of Cancer, which
has been co-edited by me and Professor Adrian Harris, we present
primary research papers and reviews that investigate poorly
explored areas of cancer metabolism and the many processes to
which dysregulated metabolism contributes.
MAPPING CANCER METABOLISM
Despite the many recent efforts, the metabolic reprogramming of
cancer cells is far from being fully characterised because of technical
and experimental limitations. In this special issue, several contribu-
tions added essential pieces to this puzzle. For instance, Berndt
et al.3 capitalise on a unique in silico modelling approach using
proteomics data not only to predict metabolic changes in liver
cancer, but also to identify metabolic pathways whose inhibition
selectively affects cancer cells. In addition, Becker4 provides an
extensive review of the regulation of pH in cancer cells and
proposes the concept of a ‘transport metabolon’, whereby multiple
transporters act together to regulate acid/base homoeostasis in
cancer cells, a key regulator of cellular metabolism.
The dysregulation of mitochondrial function remains one the
main components of the metabolic reprogramming of cancer.
Here, Raimondi and colleagues5 provide a comprehensive review of
the connection between dysregulation of electron transport chain
and cancer, focusing on the formation of reactive oxygen species
(ROS), whose role in cancer biology has never been more debated.
They propose that if, on one hand, multiple oncogenic cascades
can cause aberrant ROS production, ROS production itself can
trigger oncogenic processes, making it very difficult to disentangle
the cancer-causing role of oxidative stress. Ciccarone and
colleagues6 demonstrate that the mitochondrial enzyme aconitase
2 (ACO2) is reduced in breast cancer and, when overexpressed, it
can dysregulate pyruvate metabolism, revealing a potential
metabolic vulnerability in cancers associated with ACO2 loss.
Zhang et al.7 show that the modulation of mitofusin 1, a protein
involved in mitochondrial fusion, can also affect cellular metabo-
lism with implications for cancer biology. Indeed, they found that in
hepatocellular carcinoma, MFN1 is suppressed and its loss leads to
defects in mitochondrial metabolism and promotes metastasis.
CANCER METABOLISM IS HETEROGENEOUS AND SUBJECT TO
ENVIRONMENTAL CUES
The metabolic reprogramming of cancer is by and large
transcriptionally regulated by oncogenes and mutated tumour
suppressors. Yet, it is now clear that the metabolic composition of
the tumour microenvironment can affect the metabolic pheno-
type of the cells. Therefore, cancer cells in a tumour, exposed to
different levels of oxygen and nutrients, might be metabolically
heterogeneous and their metabolic phenotype could further
change during tumour progression, when nutrients become
limiting. In this special issue, Nanda et al.8 provide a comprehen-
sive description of the genetic and environmental cues that drive
cancer metabolism, with a specific focus on the cell-intrinsic and
cell-extrinsic factors that contribute to metabolic heterogeneity.
Importantly, as highlighted by Vettore and colleagues,9 cancer
cells and other components of the tumour microenvironment,
including fibroblasts and immune cells, form a metabolic
community and exchange metabolites regulating each other’s
functions. Intriguingly, metabolites within the tumour microenvir-
onment can affect cancer cell behaviour beyond providing energy
substrates. For instance, Sola-Penna and colleagues10 have
identified the neurotransmitter serotonin as an important player
in cell-to-cell communication mediated by the serotonin receptor.
They then show that serotonin signalling offers a proliferative
advantage to breast cancer cells by both increasing cell
proliferation and decreasing cell death.
Technical limitations of metabolomic analyses, which often
require the destruction of the tumour tissue, do not allow a full
characterisation of tumour heterogeneity. To overcome these
issues, new technologies are becoming available to analyse
metabolite levels in intact tissues. Björkblom and colleagues11
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describe the use of microdialysis to investigate the metabolic
changes in brain tumours upon treatment with the anticancer
drug cisplatin, highlighting distinct metabolic patterns associated
with the treatment. In another paper, Kawashima and colleagues12
describe the use of matrix-assisted laser desorption and ionisation
imaging mass spectrometry to investigate the distribution of
phosphatidylinositols in human tumours. They found a correlation
between the accumulation of these metabolites and invasion and
nodal metastasis in breast cancer.
TARGETING METABOLISM
A vital outcome of the work in cancer metabolism is our ability to
translate these findings into actionable anticancer targets. In this
special issue, several primary research papers provide important
examples to support that targeting metabolism can be used in the
clinic. For instance, James et al.13 show that the inhibition of the
cancer-specific pyruvate kinase 2 in pancreatic cancer cells using
shikonin reduces their growth and invasion. Intriguingly, though,
they demonstrate that this toxicity is due to the inhibition of a
pool of PKM2 localised at the plasma membrane, where it provides
a privileged ATP supply to the ATP-dependent plasma membrane
calcium pump. Therefore, the inhibition of PKM2 causes calcium
overload and cell death, rather than the expected metabolic
catastrophe. In a different context, breast cancer, Lord and
colleagues14 elegantly showed that metformin, a drug commonly
used in Type 2 diabetes but with promising yet unclear anticancer
effects, acts as an inhibitor of fatty acid oxidation at clinical doses.
This work, together with their previous finding that the
mitochondrial response to metformin in primary breast cancer
defines antitumour effect,15 suggests that metabolic profiling can
be used to predict the response to metformin, and more in
general to anticancer drugs. Finally, Liu and colleagues16 describe
the role of cystine metabolism in cancer cells and report that the
activation of the trans-sulphuration pathway to which cysteine
contributes plays a key role in the resistance to a specific iron-
dependent form of cell death defined ferroptosis.
CONCLUSIONS
In summary, many discoveries were made in this last decade in
the field of cancer metabolism. Never before have we achieved
such a comprehensive understanding of the metabolic needs of
cancer cells. We have learned that this metabolic rewiring is not
only needed to fuel energy needs or to support biomass
generation, but it has essential roles in other cancer features
such as migration, invasion, and metastasis. We have also
evidence that targeting some of these metabolic pathways can
reduce cancer growth if not as a single agent, probably in
combination with other anticancer drugs. Yet, we should not be
complacent. Indeed, emerging evidence indicates that cancer
metabolism is highly dynamic and heterogenous, and the current
analytical platforms do not enable us to grasp this complexity in
full. Better technologies to investigate metabolism at the single-
cell level without disrupting the tumour tissue are needed. If the
progress is as steady as the one we experience in the last decade, I
have no doubts we can break this barrier and achieve an even
deeper understanding of the role of metabolism in cancer.
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